Summary of Study ST002554
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001646. The data can be accessed directly via it's Project DOI: 10.21228/M8XX43 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002554 |
Study Title | Untargeted lipidomic analysis of blood plasma samples from drug-naïve patients with bipolar disorder and schizophrenia |
Study Type | Untargeted lipidomic analysis |
Study Summary | In this study, we obtained a lipidomic profile of plasma samples from patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls (CT). The sample cohort consisted of 60 drug-naïve patients and 30 control individuals. Untargeted lipidomics strategy using liquid chromatography coupled to high resolution mass spectrometry was employed to obtain the data, and univariate and multivariate statistical tools were applied to evaluate the results. Metabolic pathway networks were constructed and our results demonstrated alterations in different lipid pathways, such as glycerophospholipids, sphingolipids, and prostaglandins between schizophrenia and bipolar disorder patients. The differential diagnosis is crucial for effective treatment and improving the quality of life of patients with psychotic disorders. |
Institute | University of Campinas |
Department | Institute of Chemistry |
Laboratory | LaBIOmics - Laboratory of Bioanalytics and Integrated Omics |
Last Name | Brixner Riça |
First Name | Larissa |
Address | Laboratório B-211 a 215 - Instituto de Química, R. Josué de Castro, 126-336 - Cidade Universitária, Campinas - SP |
larissabrixner@gmail.com | |
Phone | +55 19 35213060 |
Submit Date | 2023-04-04 |
Num Groups | 3 |
Total Subjects | 90 |
Num Males | 42 |
Num Females | 48 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzML |
Analysis Type Detail | LC-MS |
Release Date | 2023-06-25 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001646 |
Project DOI: | doi: 10.21228/M8XX43 |
Project Title: | Untargeted lipidomic analysis of blood plasma samples from drug-naïve patients with bipolar disorder and schizophrenia |
Project Type: | Untargeted lipidomic analysis |
Project Summary: | In this study, we obtained a lipidomic profile of plasma samples from patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls (CT). The sample cohort consisted of 60 drug-naïve patients and 30 control individuals. Untargeted lipidomics strategy using liquid chromatography coupled to high resolution mass spectrometry was employed to obtain the data, and univariate and multivariate statistical tools were applied to evaluate the results. Metabolic pathway networks were constructed and our results demonstrated alterations in different lipid pathways, such as glycerophospholipids, sphingolipids, and prostaglandins between schizophrenia and bipolar disorder patients. |
Institute: | University of Campinas |
Department: | Institute of Chemistry |
Laboratory: | LaBIOmics - Laboratory of Bioanalytics and Integrated Omics |
Last Name: | Brixner Riça |
First Name: | Larissa |
Address: | Laboratório B-211 a 215 - Instituto de Química, R. Josué de Castro, 126-336 - Cidade Universitária, Campinas - SP |
Email: | larissabrixner@gmail.com |
Phone: | +55 19 35213060 |
Subject:
Subject ID: | SU002654 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | 15-38 |
Gender: | Male and female |
Human Exclusion Criteria: | Subjects with other psychiatric or neurological disorders were excluded |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Group |
---|---|---|
SA256483 | BD10 | BD |
SA256484 | BD09 | BD |
SA256485 | BD11 | BD |
SA256486 | BD13 | BD |
SA256487 | BD14 | BD |
SA256488 | BD08 | BD |
SA256489 | BD12 | BD |
SA256490 | BD07 | BD |
SA256491 | BD03 | BD |
SA256492 | BD02 | BD |
SA256493 | BD04 | BD |
SA256494 | BD05 | BD |
SA256495 | BD06 | BD |
SA256496 | BD15 | BD |
SA256497 | BD17 | BD |
SA256498 | BD26 | BD |
SA256499 | BD25 | BD |
SA256500 | BD27 | BD |
SA256501 | BD28 | BD |
SA256502 | BD30 | BD |
SA256503 | BD29 | BD |
SA256504 | BD24 | BD |
SA256505 | BD23 | BD |
SA256506 | BD18 | BD |
SA256507 | BD01 | BD |
SA256508 | BD19 | BD |
SA256509 | BD20 | BD |
SA256510 | BD21 | BD |
SA256511 | BD16 | BD |
SA256512 | BD22 | BD |
SA256513 | CT01 | Control |
SA256514 | CT10 | Control |
SA256515 | CT11 | Control |
SA256516 | CT12 | Control |
SA256517 | CT14 | Control |
SA256518 | CT13 | Control |
SA256519 | CT09 | Control |
SA256520 | CT08 | Control |
SA256521 | CT02 | Control |
SA256522 | CT30 | Control |
SA256523 | CT03 | Control |
SA256524 | CT04 | Control |
SA256525 | CT07 | Control |
SA256526 | CT05 | Control |
SA256527 | CT15 | Control |
SA256528 | CT06 | Control |
SA256529 | CT26 | Control |
SA256530 | CT24 | Control |
SA256531 | CT27 | Control |
SA256532 | CT28 | Control |
SA256533 | CT29 | Control |
SA256534 | CT16 | Control |
SA256535 | CT23 | Control |
SA256536 | CT25 | Control |
SA256537 | CT19 | Control |
SA256538 | CT22 | Control |
SA256539 | CT20 | Control |
SA256540 | CT21 | Control |
SA256541 | CT17 | Control |
SA256542 | CT18 | Control |
SA256543 | QC_2_4 | QC |
SA256544 | QC_3 | QC |
SA256545 | QC_2 | QC |
SA256546 | QC_1_2 | QC |
SA256547 | QC_4 | QC |
SA256548 | QC_2_2 | QC |
SA256549 | QC_2_3 | QC |
SA256550 | QC_5 | QC |
SA256551 | QC_4_2 | QC |
SA256552 | QC_5_3 | QC |
SA256553 | QC_5_4 | QC |
SA256554 | QC_4_3 | QC |
SA256555 | QC_5_2 | QC |
SA256556 | SZ26 | SZ |
SA256557 | SZ25 | SZ |
SA256558 | SZ24 | SZ |
SA256559 | SZ27 | SZ |
SA256560 | SZ30 | SZ |
SA256561 | SZ23 | SZ |
SA256562 | SZ29 | SZ |
SA256563 | SZ28 | SZ |
SA256564 | SZ08 | SZ |
SA256565 | SZ06 | SZ |
SA256566 | SZ07 | SZ |
SA256567 | SZ09 | SZ |
SA256568 | SZ10 | SZ |
SA256569 | SZ05 | SZ |
SA256570 | SZ04 | SZ |
SA256571 | SZ01 | SZ |
SA256572 | SZ02 | SZ |
SA256573 | SZ03 | SZ |
SA256574 | SZ11 | SZ |
SA256575 | SZ12 | SZ |
SA256576 | SZ18 | SZ |
SA256577 | SZ19 | SZ |
SA256578 | SZ20 | SZ |
SA256579 | SZ21 | SZ |
SA256580 | SZ17 | SZ |
SA256581 | SZ16 | SZ |
SA256582 | SZ13 | SZ |
Collection:
Collection ID: | CO002647 |
Collection Summary: | Blood samples of all subjects were collected in EDTA-coated tubes (BD Vacuntainer®, Becton Dickinson, Franklin Lakes, USA) for plasma metabolite determination after 8 hours of fasting. Samples were centrifuged at 20 °C at 1800 g for 15 minutes and were were stored at -80 ºC prior to lipid extraction. |
Sample Type: | Blood (plasma) |
Storage Conditions: | -80℃ |
Treatment:
Treatment ID: | TR002666 |
Treatment Summary: | The study was conducted at the Institute of Psychiatry, University of Sao Paulo, Brazil. The sample consisted of 60 drug-naïve patients (30 SZ and 30 BD) and 30 healthy controls (CT). All participants were under 60 years old and were middle-income, community-dwelling subjects from the hospital catchment area. SZ diagnosis was established according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (Bell, 1994) and SCID-I/P-Structured Clinical Interview Disorders Axis I for DSM-IV version 2.0 (First, 1997) was used to confirm the diagnosis. Psychopathology was assessed using the Positive and Negative Symptoms Scale (PANSS) (Kay et al., 1987) including the positive and negative subscales and general psychopathology. Depressive and manic symptoms were assessed for BD patients by the Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960) and Young's Mania Rating Scale (YMRS) (Young et al., 1978). Subjects with other psychiatric or neurological disorders were excluded. References cited: Bell, C.C. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. JAMA 1994, 272, 828–829. Spitzer, M.; Robert, L.; Gibbon, M.; Williams, J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute 2002. Kay, S.R.; Fiszbein, A.; Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987, 13, 261–276. Hamilton, M. A RATING SCALE FOR DEPRESSION. J Neurol Neurosurg Psychiatry 1960, 23, 56–62. |
Human Fasting: | 8 h |
Sample Preparation:
Sampleprep ID: | SP002660 |
Sampleprep Summary: | Plasma lipids were extracted using the SIMPLEX method (Coman et al., 2016, DOI: 10.1074/mcp.m115.053702). Briefly, the plasma samples were incubated with cold methanol and MTBE, followed by the addition of a 0.1% (m/v) ammonium acetate solution to induce phase separation. The supernatant con-taining lipids, was collected and the solvents were removed with a vacuum concentrator (Eppendorf, Hamburg, Germany). The microtubes with the extracted lipids were stored at -80 ºC prior to UHPLC-MS analysis. |
Extraction Method: | Simultaneous Metabolite, Protein, Lipid Extraction (SIMPLEX) |
Extract Storage: | -80℃ |
Combined analysis:
Analysis ID | AN004205 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | UltiMate 3000 UHPLC system (Thermo Fisher Scientific) |
Column | ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive Orbitrap |
Ion Mode | NEGATIVE |
Units | Intensity |
Chromatography:
Chromatography ID: | CH003116 |
Chromatography Summary: | Ultra-high performance liquid chromatography coupled to mass spectrometry (UHPLC-MS) analyses were performed on an UltiMate 3000 UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA) coupled to a QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific). The chromatographic separation was done on an ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters, Milford, MA, USA) and the temperature of the column oven was set to 55 ºC. The mobile phase A consisted of an ACN:water mixture (60:40) with 1 mmol/L ammonium formate and 0.1% (v/v) formic acid, and the mobile phase B consisted of an IPA:ACN mixture (90:10) with 1 mmol/L ammonium formate and 0.1% (v/v) formic acid. The flow rate was 0.4 mL/min and the injection volume was 5 μL for each sample. The gradient elution program consisted of a first linear gradient from solvent (A/B: 60/40) to solvent (A/B: 57/43) over 2 min; a rapid increase to solvent (A/B: 50/50); a second linear gradient to solvent (A/B: 46/54) over 10 min; a rapid increase to solvent (A/B: 30/70); a third linear gradient to solvent (A/B: 1/99) over 6 min; a rapid de-crease to solvent (A/B: 60/40); and finally, an isocratic elution of the solvent (A/B: 60/40) for 2 min. The column was equilibrated with solvent (A/B: 60/40) for 5 min before reuse. The total run time was 25 min for each analysis. Samples were randomized prior to analysis. To verify system stability, quality control (QC) samples were injected at the start and at the end of a run and after every 10th sample. |
Instrument Name: | UltiMate 3000 UHPLC system (Thermo Fisher Scientific) |
Column Name: | ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters) |
Column Temperature: | 55 |
Flow Gradient: | Gradient elution program (view Summary) |
Flow Rate: | 0.4 mL/min |
Sample Injection: | 5 μL |
Solvent A: | 60% acetonitrile/40% water; 1 mM ammonium formate; 0.1% formic acid |
Solvent B: | 90% isopropanol/10% acetonitrile; 1mM ammonium formate; 0.1% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS003952 |
Analysis ID: | AN004205 |
Instrument Name: | Thermo Q Exactive Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | MS scans were acquired in electrospray ionization (ESI) negative mode from m/z 100 to 1500 with a resolution of 70,000. MS target values and maximum injection time were 3 ⨯ 106 ions and 200 ms, respectively. The .raw files were converted to .mzML with the MSConvert software (ProteoWizard, Palo Alto, CA, USA). Using RStudio (RStudio, Boston, MA, USA), the parameters for data processing with the ‘xcms’ package were optimized with the ‘IPO’ package based on QC samples. With the optimized parameters, all the files were processed with ‘xcms’ and, afterwards, the data were organized in a peak list with the ‘CAMERA’ package, followed by the median fold change normalization. |
Ion Mode: | NEGATIVE |